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EIGHTH NERVE FUNCTION IN TYPE 2 DIABETES MELLITUS 
Abstrasct 
 Diabetes mellitus comprises of a group of common metabolic disorders 
that share the phenotype of hyperglycemia. Because diabetes is a systemic 
disease with accompanying pathology affecting multiple organ systems, it is 
reasonable to inquire whether the auditory system is among those 
affected.Hearing loss is one of the under recognized complications of diabetes.  
 In this study , the auditory function of 50 diabetic patients were 
compared with the same age and sex matched  20 controls. About 74 % of the 
diabetic patients had sensorineural deafness and among them about 81 % of 
the patients had mild deafness in all frequencies. Among the 23 patients who 
were recently diagnosed,  17 (69.56%) of them had hearing loss at the 
presentation, that is the patients were diagnosed only with the microvascular 
complications                     
This sensorineural deafness was statistically associated with age, 
diabetic age, and diabetic neuropathy(p<0.05). They were not related to sex, 
glycemic status except post prandial blood sugar and other microvascular 
complications. When the threshold of hearing of diabetics compared with the 
controls , diabetics had increased threshold of hearing. 
 With such high proportions of hearing loss, health care providers 
should consider providing referrals for early audiometric testing. Audiologists 
seeing middle-aged patients with unexplained hearing loss must also inquire 
about history of diabetes and family history of diabetes. 
Key words  
Diabetes mellitus , Auditory function , Hearing loss, Sensorineural 
deafness, Neuropathy.  
 
 1. INTRODUCTION 
Diabetes mellitus comprises of a group of common metabolic 
disorders that share the phenotype of hyperglycemia. It is the most 
common endocrine metabolic disorder affecting both children and adults. 
The worldwide prevalence of type 1 and type 2 diabetes mellitus is 
increasing worldwide, with especially type 2 diabetes mellitus rising 
more rapidly both in children and adults due to the recent epidemic of 
obesity and also due to lifestyle changes. Diabetes is becoming the 
epidemic of the 21st century. 
It is estimated that there are currently 366 million people with 
diabetes worldwide and this number is set to increase to 552 million by 
the year 2030 1. This equates to approximately three new cases every ten 
seconds or almost ten million per year.  International Diabetes Federation 
(IDF) also estimates that as many as 183 million people are unaware that 
they have diabetes. Diabetes affects about 6.5% of the world’s adult 
population with almost 80% of the total in the developing countries.  
Nowhere is the diabetes epidemic more pronounced than in India 
as the International Diabetes Federation (IDF) estimates the total number 
of diabetic subjects to be around 71.4 million in South East  Asia and this 
is further set to rise to 120.9 million by the year 2030 1. This constitutes 
about 20% of the total diabetic population.  
          According to the Prevalence of Diabetes in India Study (PODIS) in 
2004, the prevalence of diabetes was 4.7% in the urban and 1.9% in the 
rural areas by ADA criteria and the prevalence reported using WHO 
criteria was 2.7% and 5.6% among rural and urban areas, respectively. 
The reasons for the escalation of diabetes in Indians are   
geographic reasons and migration, stronger genetic factors, aging, 
increased insulin resistance, lower birth weight, environmental factors 
particularly associated with urbanization.  
In India, Government health expenditure accounts for just 2% of 
the total budget and 0.8% of the Gross Domestic Product (GDP)  
(World Bank Development indicators). The per capita expenditure on 
health care is only 6.4% of the average global figure, while India 
accounts for 23.5% of the world’s disability- adjusted life years lost due 
to diabetes2. Given the very limited resources available, the main thrust of 
health care provision is on the eradication of communicable diseases. 
There are also services provided by private medical practitioners for those 
who can afford the cost. 
Shobana et al3 studied the direct cost of treating diabetes in patients 
attending secondary care facilities in Chennai, in the private sector. The 
percentages of family income spent on diabetes care were 59%, 32%, 
18% and 12% in low, middle, upper-middle and upper socio economic 
groups, respectively. Urban and rural diabetic subjects spend a large 
percentage of income on diabetes management. Total median expenditure 
on health care was Rs 10,000 ($227) in urban and Rs 6,260 ($142) in 
rural (P < 0.001) subjects. The economic burden on urban families in 
developing countries is rising, and the total direct cost has doubled from 
1998 to 20054. Thus, the disease has its effects not only on the growth, 
development and emotional aspects of a person; it also carries the risk of 
long term complications with its associated morbidity and mortality with 
a significant effect on the economy as well. 
             People with diabetes commonly experience a variety of serious 
medical complications. The majority of adults with diabetes experience 
cardiovascular disease, risk factors such as hypertension, obesity and high 
cholesterol, and the risk for adverse cardiovascular outcomes such as 
stroke or a fatal cardiac event is two to four times higher among adults 
with diabetes than for those without diabetes. Diabetic retinopathy is the 
leading cause of blindness in the United States. Among Americans, 
diabetes is also the leading cause of kidney failure. Severe forms of 
diabetic nerve disease are a major cause of lower extremity amputations. 
Diabetic autonomic neuropathies can affect cardiovascular, 
gastrointestinal, bladder, and erectile function. Because diabetes is a 
systemic disease with accompanying pathology affecting multiple organ 
systems, it is reasonable to inquire whether the auditory system is among 
those affected. 
         Hearing loss is one of the under recognized complications of 
diabetes.  During the onset, with mild degrees of hearing loss, it won’t 
cause much clinically recognizable impairment. Once if it is missed to be 
screened earlier, it will progress to higher degrees of hearing loss causing 
significant morbidity in diabetic patients. 
According to comparative study of analysis of quality of life 
among elderly diabetic and nondiabetic patients, the progression of 
hearing loss was associated with worsening of indices of quality of life in 
both.  It is important for early diagnosis and monitoring of individuals 
with hearing impairment in order to improve the quality of life.18. The 
presence of some hearing loss also affects their cognitive performance.19 
            Literature did not provide much data on the incidence, type and 
degree of hearing loss & hearing loss at various frequencies. Limited 
studies are available in Indian literature to enlighten this problem. So this 
study was conceived to look into the association between hearing loss and 
type 2 diabetes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
IMMUNOPATHOLOGY OF HEARING  
LOSS IN DIABETES MELLITUS 
          Diabetes Mellitus is a common chronic metabolic disorder affecting 
both children and adults. It is characterized by chronic hyperglycemia with 
disturbances of carbohydrate, protein and fat metabolism resulting from 
defects in insulin action or insulin secretion or both. It can have long-term 
effects on the various organs of the body like the eye, kidneys, heart, 
peripheral vessels and nerves. 
The disease was first mentioned in the Eber’s papyrus as early as 
1500 B.C. The discovery of insulin by Banting et al was a significant 
breakthrough in the history of diabetes. They were followed by many 
such researchers, who have helped us to understand this disease better. 
And hence there has been a shift of terms from the older ‘Non insulin 
dependent diabetes mellitus’ and Insulin dependent mellitus’ to the newer 
‘type 1 diabetes mellitus’ and ‘type 2 diabetes mellitus’. 
Chronic complications of Diabetes Mellitus: 
            These include Retinopathy, Cataracts, Hypertension, 
Nephropathy, Neuropathy, Coronary artery disease, Peripheral vascular 
disease etc., These occur due to the effects of hyperglycemia or 
Insulinopenia on the various  tissues and can be prevented by proper 
glycemic control as was established by the Diabetes Control and 
Complications Trial (DCCT)6.  
Hearing loss and Diabetes Mellitus: 
 It has been a time honored concept that incidence of hearing loss is 
higher in persons with diabetes5.  
Pathogenesis of hearing loss in diabetes:  
Diabetes-related hearing loss may be sensineural, whereby a 
cochlear or neural lesion impedes the transmission of auditory signals to 
the brain 
Hearing loss occurs by three possible path physiological 
Mechanisms:-                        
1.  Diabetic Microangiopathy of Cochlea 
2.  Diabetic Neuropathy of Cochlear nerve 
     3.  Combination of above  
 
 
 
 
 
 
Diabetic Microangiopathy of Cochlea: 
(i)  Thickness of walls of capillaries in striavascularis: 
 Major immune pathology in Diabetic Microangiopathy is 
increasing  thickness of capillary wall in striavascularis.  
          Fukushima H et al7 studied in 2006 with temporal bones of 
18 diabetic patients with type 2 DM and showed that  in the insulin 
group, walls of the vessels of The basilar membrane and stria 
vascularis in all turns were significantly thicker than those of 
controls. Walls of the vessels of the stria vascularis in the basal 
turn were also significantly thicker in the oral hypoglycemic group 
than in controls. Atrophy of the stria vascularis in most turns  of 
the insulin group and the lower middle turn of the oral 
hypoglycemic group was significantly greater than in the controls  
 
 Figure 1-a.  There is thickening of the capillary walls in the stria 
vascularis in lower middle turn of the cochlea from a 39-year old female 
with a 33-year-history of type 1 diabetes mellitus. HE, x200. 
Figure 1-b.  There is total occlusion of a capillary (arrow head) 
and complete loss of stria vascularis in lower middle turn of the cochlea 
from a 38-year old female with a 19-year-history of type 1 diabetes 
mellitus. HE, x200. 
 
(ii)  Loss of outer hair cells: 
Loss of outer hair cells in basal turn of cochlea is another proposed 
pathological change in cochlea causing hearing loss in diabetes. 
Wackym-pa et al8 studied temporal bones of 68 Type 1 diabetic patients 
and found that significant loss of outer hair cells in diabetics ( 24.3%+SD 
16.6) compared with controls (15.4%+SD 4.1) in the lower basal turn.  
Finally he concluded that there was a correlation between loss of outer 
hair cells in lower basal turn and increased thickness of capillary wall in 
basilar membrane in diabetics.  
(iii)  Atrophy of Striavascularis: 
Atrophy of Striavascularis is another important histopathological 
change in microangiopathy of cochlea causing hearing loss in diabetes. 
Makishima K, et al8 conducted a study in 1996 and showed that total area 
of all five turns of Striavascularis in diabetics (19808 m2+ SD 6910) 
was significantly lower than controls ( 32113 m2+ SD 4302) . He also 
correlated the thickness of capillary wall in basilar membrane and atrophy 
of Striavascularis. This further confirmed by another study by 
TomisawaH in 2000 13 
(iv)  Loss of Spiral Ganglion cells: 
Loss of Spiral Ganglion cells in cochlea can cause hearing loss, and 
it was proved by Costa OA et al9 in 1993. From his study, he observed 
that there is significant loss in number of spiral Ganglion cells in any 
segment of cochlea between Diabetics and controls. 
II)  Diabetic Neuropathy of Cochlear Nerve: 
This is another patho physiology of hearing loss in diabetes next to 
diabetic microangiopathy. Like other Neuropathy occurring in diabetes, 
Auditory Neuropathy can cause hearing loss10. Friedman et al showed in 
his study that his diabetic patients with peripheral neuropathy had high 
threshold of hearing secondary to auditory neuropathy.  ABR recordings 
revealed that absolute latencies of waves I, III and V were prolonged 
significantly in the diabetic group when compared to the control group (p 
< 0.05). When two diabetic groups (insulin-dependent and non-insulin-
dependent) were compared with each other, the difference between the 
latency of wave I and the inter-peak latencies of I–III, III–V and I–V was 
not significant ( p > 0.05). However, the difference between the latencies 
of waves III and V in the two diabetic groups was statistically 
significant.23 
            Even though both diabetic microangiopathy and cochlear 
neuropathy can cause hearing loss, most studies21,22 favors 
microangiopathy theory as a major pathophysiology of hearing loss.  
          Oxidative stress may play an important role in hearing impairment 
in diabetic patients.  In this process, increased protein oxidation appears 
to be more important than lipid per oxidation. Nitric oxide may have a 
protective effect on hearing, as may some nonenzymatic antioxidants 
such as vitamin C and E. The nitric oxide level was significantly 
increased in the diabetic group with good hearing, compared with 
diabetic patients with hearing loss (p = 0.014). In the diabetic group, a 
clear, negative correlation was observed between serum levels of nitric 
oxide and vitamins C and E, and hearing impairment (r = -0.395, r = -
0.318, r = -0.500, respectively)35 
 
 
 
 
 
 
 
 
LITERATURE REVIEW 
   Association  of hearing loss with diabetes has been spoken since 
olden times .The relationship between type 1 DM and hearing impairment 
has been a subject of debate since Jordao et al14 reported a case of hearing 
loss with incipient diabetic coma almost 150 years ago... Despite a 
number of studies on hearing function in diabetic patients with well-
controlled disease, conflicting data still exist on a possible association 
between bilateral progressive high frequency hearing loss and diabetes.  
Incidence of hearing loss in diabetes: 
Kakal Paudi et al15 on May 2003 conducted a retrospective data 
base review from 1989 to 2003, concluded that sensorineural hearing loss 
was more common in patients with diabetes than in the control 
nondiabetic patients. He also observed that the severity of hearing loss 
seemed to correlate with progress of disease as reflected in Sr. Creatinine 
and glycosylated Hb level (HbA1c). This may have been due to 
microangiopathic disease in inner ear. 
 
 
 
Incidence of hearing loss in diabetes in older studies: 
            Several authors reported a higher incidence of hearing loss in diabetic 
patients in comparison to the general population.  
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Camisasca et 
al.(1950) 
81 29-75 absent 1 present Present DSN in 46% of 
cases 
Jorgenson 
&buch(1961) 
69 16-73 present 1 absent w/ retinopathy 
and nephropathy 
41% DSN bilateral 
Tota & bocci(1965) 100 11-80 present 1&2 present retinopathy 9 dB—6KHz 
15dB—3KHz 
>61—70 years 
Marulo et al(1974) 60 20-49 present 1&2 present Retinopathy, 
coronaryopathy, 
peripheral 
angiopathy 
DSN in 30% of 
cases 
Friedman et 
al.(1975) 
20 22-70 present 2 present Peripheral 
neuropathy, 
retinopathy and use 
of AB 
DSN in 55% of 
cases 
Taylor & 
Irwin(1978) 
77 15-62 present 1 absent absent DSN mild below 
9Db 
Ferror et al.(1991) 46 14-40 present 1 present Retinopathy and 
nephropathy 
30 dB in atleast one 
frequency 
Cullen 
&cinnamond(1993) 
44 Mean 46.9 
present 
1 absent No data P<0.001 
high frequency 
Tay et al.(1995) 102 19-80 absent 59—143—
2Present 
No correlation Low and medium 
frequencies 
p<0.001 
Dalton et al(1998) 344 43-84 present 2 absent No association with 
retinopathy; 
association with 
nephropathy 
High frequencies 
Above 4000 Hz 
However, there are other studies with more subjects and better 
designed that did not identify this association (Table 2). 
 
 
 
 
AUTHOR NO OF 
PATIENTS 
AGE  
INFLUENCE 
OF AGE 
TYPE OF 
DM  
INFLUENCE 
OF  
DURA
TION 
RELATION W/ 
PRESENCE  
OF 
COMPLICATIONS 
DM 
AFFECTED 
FREQUENCIES
LOSS IN 
DECIBEL 
Profazio 
& 
barraveli 
(1959) 
40 9-70 present 1 present Neuropathy 
retinopathy and use 
of AB 
DSN in 55% of 
cases >44 yrs 
Strauss et 
al.(1982) 
660 65 present 1&2 absent Other factors, 
hypertension, noise 
exposure 
Significant 
abnormalities 
were not found 
Miller et 
al.(1983) 
33 22-72 
present 
1 absent Other factors, 
noise exposure 
Significant 
abnormalities 
were not found 
Axellson 
& 
fagerburg 
(1968) 
99 16-59 present 1 absent No correlation Significant 
abnormalities 
were not found 
Espania et 
al.(1995) 
47 7-47 present P=0.0143 No correlation DSN in 30% of 
cases 
Association of hearing loss in diabetes in various recent studies 
   According to a study by D’Espana et al conducted in 199515, 
incidence of hearing loss was found in 30% of cases. Hearing loss was 
significantly correlated with age (p = 0.0019) and duration of diabetes (p 
= 0.0143), but not with diabetic microangiopathy (p = 0.1506).  
   Another study conducted in CMC Vellore in 1989, showed that 
diabetics had a poorer hearing threshold than the non-diabetics; all age 
groups with diabetes showed a significant high frequency hearing loss, as 
compared to the control population; poorly controlled and complicated 
diabetics have significant, high frequency hearing loss as compared to 
those who were well controlled and uncomplicated; there was no 
relationship between duration of the diabetes and the level of hearing 
loss. 
 Rózańska-Kudelska M et al conducted a study in 2002, showed 
subjects with diabetes type 2 were more likely to have a hearing loss than 
were subjects without diabetes (95% vs. 65%). 
        Another study conducted in 2009 found statistically 
significantly worse audiometric thresholds among patients with diabetes 
mellitus (about 38% of sensori neural deafness) when compared to 
patients in the control group.20 
According to Audiometric Evidence from the National Health and 
Nutrition Examination Survey, 1999 to 2004 ,  the prevalence of low- or 
mid-frequency hearing impairment of mild or greater severity of 28.0% 
among people with diabetes. The prevalence of hearing impairment was 
higher among individuals with diabetes in both sexes; all groups of race 
or ethnicity, education, and income–poverty ratio; and all age groups. 
This is one of the largest national surveys conducted so far. 
Hearing loss and age of the patient  
    Hearing loss increases as the age advances. According to the 
study by Mitchell P et al, age-related hearing loss was present in 50.0% 
of diabetic participants (n = 210) compared with 38.2% of non-diabetic 
participants. Accelerated hearing loss progression over 5 years was more 
than doubled in persons newly diagnosed with diabetes.28  
 
Hearing loss and diabetic age: 
Hearing loss occurs more frequently as diabetic age advances. Tay 
et al12 showed in his study of 102 diabetic patients, that the threshold of 
hearing was higher in low and mid frequencies and it was positively  
correlated with diabetic age. He observed that the diabetic age advances 
by more than 5 years, there is higher incidence of hearing loss. 
Hearing loss in various frequencies: 
Hearing loss in diabetes occurs commonly in mid and high 
frequencies as the basal turn of cochlea is more affected. De epsana et al15 
conducted a study in Barcelona university Spain with two groups  
(Group I: early diabetics, group II: chronic diabetics). In group 1 (17/47) 
patients developed hearing loss at high and mid frequency, in group II 
(30/47) patients developed hearing loss at all frequencies. He concluded 
that diabetes initially affects basal turn of cochlea as evidenced by mid 
and high frequency hearing loss in early diabetics. As diabetic age 
advances with involvement of apical turn of cochlea, there will be hearing 
loss at all frequencies in chronic diabetics. 
 
Hearing loss and Metabolic Control: 
Hearing loss in diabetes significantly correlated with degree of 
metabolic control (Glycosylated Hb). 
Lack of glycemic control shows a positive correlation with extent 
of hearing loss when compared to those diabetics with good glycemic 
control. This is noted in all the frequencies tested. Both Kurien16 and 
Lasisi32 show similar findings. A possible mechanism to explain this 
observation could be the cumulative effects of advanced glycation end 
products on the inner ear. High post-prandial blood sugar levels cause a 
significant alteration in high frequency hearing thresholds in diabetics. 
Damage to outer hair cells by sustained hyperglycemia has been noted in 
animal studies. Currently, outer hair cell function in diabetes is an area of 
intense research activity. 
Hearing loss and Retinopathy, Nephropathy: 
Microangiopathic complications like nephropathy and retinopathy 
are correlated with hearing loss. Ferrer et al34 and Elamin et al22 
performed a study with 98 diabetic children in 1991.  They observed that 
hearing loss was positively correlated with background and proliferative 
diabetic retinopathy and nephropathy, because all of these three 
complications are different spectrum of diabetic microangiopathy.  
Peripheral neuropathy and Hearing loss: 
Cochlear neuropathy is another important cause of hearing loss in 
diabetes. Cochlear neuropathy in diabetes is either due to direct insult 
induced injury by chronic hyperglycemia or by microangiopathy of vasa 
nervosa of cochlear nerve was not clearly known. Celik O et al21 and 
Huyang et al23 observed from their studies that cochlear neuropathy 
identified by BERA causing hearing loss was positively correlated with 
peripheral neuropathy identified by Nerve conduction studies (NCS).  
 
OBJECTIVES OF THE STUDY 
 
1. To assess the auditory function in the diabetic patients.   
2. To know the incidence of hearing loss in diabetic and non diabetic 
patients. 
3. To assess the degree of hearing loss and its distribution in various 
frequencies. 
4. To analyze the effect of age, glycemic status (FBS, PPBS), (HbA1C), 
duration of type 2 diabetes on auditory acuity.  
5. To compare association of hearing loss with peripheral neuropathy and 
other complications. 
6. To compare the threshold of hearing in diabetic patients    without 
hearing loss and non diabetic patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
The study was conducted at Department of Diabetology, Madurai 
Medical College, a tertiary care hospital, Madurai during the period between 
May 2011 and September 2011. It was carried out with case control study 
design. 
Source of data 
Study population was classified into two groups.. Group 1 comprises of 
50 type 2 diabetic patients of either sex selected from the Department of 
Diabetology, belonging to the ages between 35 and 60 years. Group 1 comprises 
of 20 normal, healthy subjects of either sex selected from the patient attendees 
in hospital, belonging to the same age group . 
Method of collection of data 
The study comprising of 50 type 2 diabetics and 20 nondiabetics, 
matched with respect to age and sex are selected based on inclusion and 
exclusion criteria. 
Inclusion criteria for diabetic patients 
Fifty type 2 diabetic patients between the ages 35 and 60 years who had 
given written consent were included.  
 
 
Inclusion criteria for controls  
 Age matched twenty normal healthy subjects of either sex who had given 
written consent  were included. 
Exclusion criteria  
1. History of consumption of ototoxic drugs in past three months. 
2. History of ear surgeries performed in the past. 
3. History of ear infections in the past. 
4. History of recent infections in the nose, throat or ear. 
5. Patients having a noise induced hearing loss (as shown by pure tone 
audiometry at 4000 Hz 
6. Patients with other comorbid diseases which could cause hearing 
problems 
Maneuver: 
The study was conducted at the Government Rajaji Hospital, Madurai 
between the periods of May 2011 to September 2011. The cases were enrolled 
for the study from the Diabetology OPD at the hospital. Patients were selected 
randomly from this group and were enrolled into the study. 
All patients are treated with human insulin or anti-diabetic drugs provided 
by our diabetic clinic. Blood glucose is estimated once in three months when the 
patient is attending the diabetic clinic.  
Before doing hearing assessment, age at onset of Diabetic Mellitus was 
noted to calculate the approximate diabetic age of the patient. Previous history 
of hearing impairment, ear discharge, head or ear trauma and family history of 
congenital deafness were enquired. Other chronic complications like 
nephropathy, retinopathy were assessed.  
             Retinopathy was assessed by retinal examination. Nephropathy was 
assessed by estimation of blood urea, serum creatinine and electrolytes. Diabetic 
Neuropathy was clinically assessed by vibration test and sensation tested using 
monofilament. Then clinical assessment of hearing was done in all patients by 
doing Rinne’s test, Weber’s test, and ABC conduction test. Those who were 
able to understand and reciprocate the above clinical tests were subjected to 
undergo otoscopic examination and Pure tone audiometry using Am plaid 300 
clinical audiometer. None of the study population had any ear pain or hearing 
loss following an exposure of excessive noise or sound. Following a thorough 
ENT examination, pure tone audiometry was performed in a sound proof room 
for both cases and controls. Both air and bone conductions were tested at low, 
mid and high frequencies 
PURE TONE AUDIOMETRY 
 
Principle:  
An audiometer [ARPHI 500 MK 1] is an electronic device that produces 
pure tones, the intensity of which can be increased or decreased in 5-Db steps. 
Air conduction thresholds are measured for tones of 250, 500, 1000, 1500, 
2000, 4000 6000 and 8000 Hertz. Bone conduction thresholds and measured for 
250, 500, 1000, 1500, 2000, 4000 Hertz. The amount of intensity that has to be 
raised above the normal level is a measure of the degree of hearing impairment 
at that frequency. It is charted in the form of a graph called the “audiogram.” 
The thresholds of bone conduction are a measure of the cochlear function. The 
difference in the thresholds of air and bone conduction (A-B gap) is a measure 
of a degree of conductive deafness. The audiometer is so calibrated that hearing 
of a normal person, both of air and bone conduction is at 0 db and there is no A-
B gap[13] 
Methodology of pure tone audiometry:- 
The method is based on American Society for Speech and Hearing 
Association [ASHA] 1978 guidelines for manual Pure Tone Audiometry (PTA). 
Masked pure tone audiometry is done if there is a difference of more than 40 dB 
between air conduction threshold of the test ear and the bone conduction 
threshold of the opposite ear, or when the air bone gap of the poorer ear under 
test is more than 10 dB. 
Definition of Hearing Loss: 
Any person with average threshold of hearing more than 25 db in 
any frequency by Pure Tone Audiometry was considered to have hearing 
loss. 
Audiometry was done in 3 different frequencies. 
1.  Low frequency (250 to 1000 Hz) 
2.  Mid frequency (1000 to 4000 Hz) 
3.  High frequency (4000 to 8000 Hz) 
Degree of hearing impairment were analyzed according to WHO 
classification 
DEGREE OF HEARING LOSS 
1. Mild :-  26 to 40 db 
2. Moderate :-  41 to 55 db 
3. Moderately severe :-  56 to 70 db 
4. Severe :-  71 to 91 db 
5. Profound :-  >91 db  
The results are discussed subsequently 
Statistical methods [14, 15] 
Chi square test has been used to find the significance of auditory 
thresholds (dB) between various categories of parameters. Analysis of variance 
[ANOVA] has been used to find the significance of auditory thresholds in 
different age groups and duration of the disease.  
Statistical software: 
The statistical soft ware namely SPSS 11.0 and Systat 8.0 were used for 
the analysis of the data and Microsoft Word and Microsoft Excel have been 
used to generate graphs, tables, etc. 
 
 
 
 
 
 
 
 
RESULTS 
The results were analyzed as follows:- 
i. Presence of hearing loss in diabetic and non diabetic patients 
ii. Profile of hearing loss  
iii. Risk factor for hearing loss  
iv. Co morbidities of diabetes and hearing loss 
v. Hearing thresholds of all diabetic patients were compared 
with controls 
Fifty diabetic patients screened (32 males,18 females),of mean age 49.94 
were recruited. The mean duration of diabetes was 2.64 yrs. The mean fasting 
glucose, mean postprandial blood glucose and mean HbA1c were 170.4 mg/dl , 
294.26mg/dl , 8.728 respectively. In the fifty diabetic patients only 13 of them 
had normal hearing. 
     
TABLE- 3: PRESENCE OF HEARING LOSS IN DIABETIC AND 
NONDIABETIC PATEINTS 
Study Population 
Hearing 
Loss 
Present 
Hearing 
Loss 
Absent 
n % n % 
Diabetic patients 37 74% 13 26% 
Non diabetic 
persons 
3 15% 17 85% 
P valve = 0.001 
In this study 37 (74%) diabetic patients had hearing loss. Whereas only 3 
(15%) of the healthy individuals had hearing loss. 
Analysis shows that there is significant difference in incidence of hearing 
loss between diabetic patients and non diabetic patients 
  
PROFILE OF HEARING LOSS IN DIABETIC PATIENTS 
About 81% of the patients had sensori neural deafness. Only 4(8%) had 
conductive deafness in addition to sensori neural deafness. 
Sensory Neural Hearing Loss in Various Frequencies  
In the 37 patients with deafness, 30(81%) of them had hearing loss in all 
frequencies. And 6 (18.91%) had hearing loss only in the mid and high 
frequencies.  
TABLE4: Sensory Neural Hearing Loss in Various Frequencies  
Hearing loss severity 
All frequency hearing 
loss 
 
 n 
Mid/high frequency 
hearing loss 
n 
Mild (25-40db) 25 5 
Moderate (40-55 db) 1 1 
Severe 
 (>55db) 
4 1 
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THE FOLLOWING FACTORS WERE ANALYZED FOR HEARING 
LOSS IN DIABETIC  PATIENTS  
i) Gender of diabetic patients 
ii) Age of diabetic patients 
iii) Diabetic Age (duration between the date of diagnosis of diabetes 
and date of first hearing assessment) 
iv) Glycosylated hemoglobin  
v) Co morbidity relating to involvement of other organ systems in 
diabetes 
a. Neuropathy 
b. Nephropathy and  
c. Retinopathy 
  
(i). Gender And Hearing Loss  
  In the study group, there were 32 males (64%) and 18 females (32%). In 
the 32 males, 19 had hearing loss in all frequencies, 6 had hearing loss only in 
mid and high frequencies. In females, 11 had all frequency loss while one had 
mid and high frequency loss 
TABLE 5: DISTRIBUTION OF HEARING LOSS BASED ON GENDER 
SEX TOTAL HEARING 
LOSS   + 
NORMAL 
MALE 
32 25
 
7 
FEMALE 
18 12
 
6 
When analyzed using chi square, p value between these two groups 
ranged from   0.189- 0.990 and there is no significant difference in incidence of 
hearing loss according to gender. 
TABLE 5 B: DISTRIBUTION OF FREQUENCY OF HEARING LOSS 
BASED ON GENDER 
SEX ALL 
FREQUENCY 
LOSS 
MID/HIGH 
FREQUENCY 
LOSS 
MALE 
19
 
6 
FEMALE 
11
 
1 
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(ii). Age of diabetic persons and hearing loss 
Incidence of total hearing loss were analyzed with respect to age . 
Patients were grouped into   three  groups as 35-45 yrs, 46-55 yrs, > 55yrs, and 
performed the exercise of Pure tone Audiometry..There were 13 patients in the 
group of 35-45 yrs, 24 in the group of 46-55yrs, 13 patients in the group of > 
55yrs 
CHART - 2:AGE DISTRIBUTION
 
  
0
5
10
15
20
25
35 - 45 46 - 55 > 55
13
24
13
N
O
.O
F 
C
AS
ES
AGE DISTRIBUTION
 TABLE7: DISTRIBUTION OF HEARING LOSS IN DIFFERENT AGE 
GROUPS 
 
Age 
yrs Mild Moderate Severe 
% of persons 
having hearing 
loss 
35 - 45  7 0 0 
 
53% 
46 - 55  15 3 1 
 
79% 
> 55  7 3 1 
 
84% 
 
In the age group of 35-45 yrs,  only 7 (53%)patients had mild hearing 
loss. In the age group of 46-55yrs, 15 patients had hearing loss in the mild form, 
3 had moderate hearing loss,and 1 had severe hearing loss. In the age group of 
greater than 55 yrs, 7 had mild hearing loss, 3 had moderate hearing loss, and 
one had severe hearing loss.Analysis through ANOVA – ONE WAY 
ANALYSIS showed it to be statistically significant. As the age increases the 
incidence of hearing loss also increased. 
  
 
 
(iii). Diabetic age and hearing loss  
Incidence of hearing loss in diabetic patients were analyzed with respect 
to diabetic age less than 1yr, 1 - 5 yrs and between 5-10 yrs,  
since diabetic age in the study population ranging from 1 yr to maximum of  10 
yrs. 
In the patients with diabetic age of less than one year (27), 21(77.7%)  
had hearing loss. Out of them  15 had mild hearing loss, 2 had moderate hearing 
loss, and 4 had severe hearing loss. 
In the group of patients with 1-5 yrs(11) of diabetic age, 6 had mild 
hearing loss.  Patients with diabetic age above 5 yrs (12), 10 had hearing loss;  9 
of them had mild hearing loss and 1 had severe hearing loss. 
Diabetic age was statistically associated with hearing loss. (p=0.001) 
when analyzed by one way ANOVA 
 
TABLE 8: Diabetic age and hearing loss 
Diabetic Age 
 
Total cases 
n 
Mild 
n 
Moderate 
n 
 
Severe 
n 
 
< 1 
 
27 15 2 4 
 
1 - 5 
 
11 6 0 0 
 
> 5 
 
12 9 0 1 
 
 
CHART – II DISTRIBUTION OF HEARING LOSS IN AMONG 
PATIENTS WITH DIFFERENT DIABETIC AGES 
 
 
  
0
2
4
6
8
10
12
14
16
Mild Moderate Severe
≤ 1
1 ‐ 5  
> 5
Distribution Of Hearing Loss In Various Frequencies 
Patients with diabetic age <1 yr, 15 patients had all frequency loss and 6 
patients had mid/high frequency loss. In patients with diabetic age from 1-5 yrs  
all had all frequency loss. In patients with diabetic age more than 5 yrs , 9 
persons had all frequency loss while one patient had high frequency loss. But 
the diabetic age was not statistically associated with the frequency of hearing 
loss (p>0.05)as shown in the table 9 
 
DISTRIBUTION OF HEARING LOSS IN VARIOUS FREQUENCIES 
TABLE9 
Diabetic Age All frequency Mid/high frequency 
≤ 1 15(55.55%) 6(22.22%) 
1 - 5 6(54.54%) 0 
> 5 9(75%) 1(8%) 
 
 
(iv). Glycosylated Hb and hearing loss  
Metabolic control of diabetes was assessed by estimating glycosylated 
Hb. Incidence of hearing loss in diabetic patients were analyzed with respect to 
Glycosylated Hb (HbA1c) between < 7 and >7, since the goal of mean HbA1c < 
7 as per ADA guidelines 2011. Among the fifty patients only 12 had HbA1C 
less than 7.Out of them, 7 had mild hearing loss, 1 had moderate hearing loss,1 
had severe hearing loss. In the patients with poor control, 23 of them had mild 
hearing loss, 1 had moderate hearing loss, 4 had severe hearing loss.as shown in 
table10 
               TABLE10 ­ GLYCOSYLATED HB AND HEARING LOSS  
 
 
Severity of hearing loss 
 
Hba1c < 7 Hba1c >7 
Mild 7 23 
Moderate 1 1 
Severe 1 4 
Normal  3 10 
  The metabolic control was not statistically significantly associated with 
hearing loss.(p>0.05) 
  
Glycoslated Hb and frequency of hearing loss 
In patients with good glycemic control, 8 persons had all frequency loss 
and 1 had high frequency loss. In patients with inadequate control, 22 had all 
frequency loss and 6 had high frequency loss. Frequency of hearing loss was 
also not associated with glycemic control(p>0.05) 
TABLE 11 - GLYCOSLATED HB AND FREQUENCY OF HEARING 
LOSS 
Hearing loss Hba1c < 7 Hba1c >7 
All frequency 8(88.88%) 22(78%) 
Mid /high frequency 1(11.11%) 6(21.42%) 
  
(v). Fasting  blood sugar and hearing loss 
Patients were classifed into two groups based on fasting blood sugar 
control. There were 16 patients with FBS < 126 mg/dl; 32 patients with FBS > 
126mg/dl. In the patients with adequate control of FBS, 12 patients had hearing 
loss while patients with inadequate control, 25 had hearing loss. There was no 
statistical significance among them based on the hearing loss. 
TABLE12 - FASTING  BLOOD SUGAR AND HEARING LOSS 
FBS 
 
Total 
cases 
 
Mild 
 cases 
Moderate
 cases 
Severe 
 cases 
< 126mg/dl 16 10 0 2 
>126mg/dl 32 20 2 3 
The relationship of fasting blood sugar was again analysed with hearing 
loss at variable frequency. Patients with FBS <126 mg/dl 10 had mild hearing 
loss and 2 had severe hearing loss. While patients with FBS>126 mg/dl 20 had 
mild hearing loss and 2  had moderate hearing loss and 3 had severe hearing 
loss.They were also not significantly associated (p > 0.05) 
 
 
TABLE13 DISTRIBUTION OF HEARING LOSS BASED ON 
FREQUENCY 
FBS All frequency Mid/high frequency 
< 126 12(100%) 0 
>126 18(72%) 7(28%) 
Usually hyperglycemia is associated with mid/high frequency hearing 
loss as shown in Table 13. 7 patients with inadequate glycemic control had high 
frequency loss 
(vi). Postprandial Blood Sugar And Hearing Loss Among Diabetic Patients 
In patients with good conrol of postprandial blood sugar(4), only 1 had 
hearing loss as shown in Table 14. Postprandial blood sugar was statiscally 
associated with hearing loss (p value < 0.05) When the post prandial blood 
sugar and frequency of hearing loss among diabetic patients were analyzed, 
again hyperglycemia was associated with high frequency loss as shown in Table 
15. None of the patients with PPBS < 200 mg/dl had high frequency hearing 
loss.  
 
 
 
TABLE 14 - POSTPRANDIAL BLOOD SUGAR AND HEARING LOSS 
AMONG DIABETIC PATIENTS 
 
 
TABLE15 - FREQUENCY OF HEARING LOSS BASED ON 
POSTPRANDIAL BLOOD SUGAR 
PPBS ALLFREQUENCY HEARING LOSS 
MID/HIGH 
FREQUENCY 
<200 
 
1 
0 
>200 
 
29 
7 
 
(vii). Hearing Loss and Chronic Complications:- 
Patients that were included for the study did not have diabetic retinopathy 
or diabetic nephropathy. 
PPBS 
 
TOTAL CASES 
 
HEARING LOSS + NORMAL 
< 200 4 1 3 
> 200 46 36 10 
When assessed for diabetic neuropathy using vibration test and 
monofilament test, 26 patients had diabetic neuropathy while 24 did not have. 
When its correlation with hearing loss was studied, it was statistically 
significant(p<0.05). 
 22 patients with diabetic neuropathy had all frequency loss and 2 
patients had mid/ high frequency loss while in the patients without diabetic 
neuropathy 8 patients had all frequency loss.  
TABLE 16 DIABETIC NEUROPATHY AND FREQUENCY OF 
HEARING LOSS 
Frequency of hearing loss Neuropathy + Neuropathy - 
All frequency 22(84%) 8(33%) 
Mid/high 2(7%) 5(20.8%) 
Normal  2 11 
 
Severity of hearing loss among diabetics with neuropathy 
In the patients with neuropathy 20 had mild hearing loss, 1 had moderate 
hearing loss,and 4 had severe hearing loss as shown in chart 3. In the patients 
without neuropathy, 10 had mild hearing loss, 1 had moderate hearing loss and 
2 had severe hearing loss.  
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 DISCUSSION 
Comparison with other Studies and Literature Review:- 
Review of literature shows that hearing loss is more common in 
diabetics18. The incidence of hearing loss in diabetic patients in this study was 
74% while it was about zero to 93% 11, 17.in various other studies. Many have 
tried to identify the cause, and based on their conclusions, the probable 
mechanisms are microangiopathy of the inner ear, neuropathy of the cochlear 
nerve, a combination of both, outer hair dysfunction and disruption of end 
lymphatic potential. 
 Elamin et al22 favors microangiopathic theory, which is supported by 
histopathological findings on temporal bones and inner ear. Thickening of 
capillary wall with secondary ischemia in the cochlea and the 8th cranial nerve 
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have been demonstrated in diabetic patients and experimental animal models by 
Durmus et al on 198023.This study demonstrates a significant hearing loss in 
diabetics in all the frequencies tested. This could be explained by 
microangiopathy of the vessels to the inner ear as proposed by Wackym.39 or 
due to the chronic nature of the disease as explained by De Espana15  
The effect of age on auditory thresholds in diabetic subjects was 
found to be clinically and statistically significant. This was similar to the 
results of De Espana (1995). He found a correlation between hearing levels and 
age of the subjects in the diabetic group15, and concluded that any hearing loss 
due to diabetes will be additional to that due to age alone. Similar conclusions 
were drawn by Axelson.41.These results were not similar to Kakarlupudi42 and 
Dalton43studies.There also few studies to suggest that persons with diabetes may 
experience hearing loss at earlier ages.46 
 There was also positive correlation between the duration of diabetes 
and hearing loss similar to the results of Tay et al 12.Among the 50 patients, 23 
patients were recently diagnosed to have diabetes mellitus. Out of these 23 
patients ,17 (69.56%) of them had hearing loss at the presentation.10 of them 
had hearing loss  in all frequencies indicating that they were chronic diabetics15. 
Thus the recognition of the disease in our population is generally late i.e 
only after the development of  microangiopathic complications. 
Although many studies showed correlation with glycemic control and 
hearing loss, there was no significant association between the patients with good 
glycemic control (HbA1C) and poorly controlled diabetes in this study. This 
was similar to the results of the study by Weng et al in 2005.44There was also no 
correlation with blood glucose levels similar to the results of Durmus23. 
However post prandial blood sugar > 200 mg/dl was significantly associated 
with hearing loss. 
This study also did not find have any correlation with diabetic retinopathy 
and nephropathy. This was similar to Lisowska G 45 . According to them, there 
was no correlation between diabetic micro vascular complications and DPOAE 
amplitudes reduction. And they indicate the existence of an alteration in 
cochlear micromechanics in diabetic patients with microangiopathy as well as in 
patients without microangiopathy. The lack of significant correlation between 
the degree of micro vascular complications in the retina or kidneys and 
DPOAEs amplitude reduction suggest that the impaired functional properties of 
the outer hair cells are probably caused by early metabolic complications in 
diabetes (among other things non-enzymatic glycation related to hyperactivity 
of free oxygen radicals) and not directly by diabetic microangiopathy. Oxidative 
stress is an imbalance between ROS and antioxidant defense systems of the 
body. This may result from the alteration of glucose metabolites or due  to 
secondary mechanisms to activation or dysregulation of several enzymes not 
directly involved in glucose metabolism. 
Diabetic neuropathy was significantly associated with hearing loss 
indicating there is associated auditory neuropathy. Frequency of hearing loss in 
auditory neuropathy can be of any type. This is depends on the site of dysfunction. 
The low frequency hearing loss in auditory neuropathy arise from the lesion of 
retrocochlear auditory afferent and efferent nerve and auditory brainstem. The high 
frequency hearing loss in auditory neuropathy arise from the lesion of cochlear outer 
hair cells47.  
   The incidence of hearing loss is as high as 75% in our population. And it is 
usually under recognized. With such high proportions of hearing loss, health care 
providers should consider providing referrals for early audiometric testing. 
Audiologists seeing middle-aged patients with unexplained hearing loss must also 
inquire about history of diabetes and family history of diabetes. 
   Early recognition of the disease and its complications is important. And all 
newly diagnosed patients should be periodically screened for its microvascular 
complication. Patients with diabetes should be encouraged in their efforts to maintain 
good and early control of  blood glucose in accordance with guidelines from the 
American Diabetes Association (2010) thereby preventing the early complications of 
oxidative stress. Good glycemic control is difficult to achieve in many patients with 
diabetes and microvascular complications can occur even with intensive insulin 
therapy. Therefore there should be development of therapy that targets signaling 
pathways that cause vascular dysfunction  and ultimately diabetic complications is 
also important. People with damaged ears  should be recognized early and 
rehabilitated early with hearing aids.  
 
SUMMARY OF THE STUDY 
From the analysis of hearing loss in diabetic patients, 37 (74%) diabetic 
patients were identified to have Sensori neural hearing loss. Only 4 patients had 
conductive deafness. Majority of them (81%) had mild degree of hearing 
impairment (26-40 db).When the threshold of hearing of diabetics compared 
with the controls , diabetics had increased threshold of hearing. 
Out of the 37 diabetic patients with hearing loss, about 4/5th of them were 
identified to have hearing impairment at all frequencies and less than 1/5th had 
hearing impairment at mid/high frequency.  
Associations of various risk factors and co morbidities with hearing loss 
were analyzed. There is statistically significant association between hearing loss 
and diabetic age and age of the patient. There is no statistically significant 
association between gender, age at onset of diabetes mellitus, metabolic control 
(Glycosylated Hb), chronic complications like nephropathy, retinopathy, and 
hearing loss. However, diabetic neuropathy is associated statistically significant 
with hearing loss. Patients with high post prandial blood sugar were statiscally 
associated with hearing loss.  
 
 
CONCLUSIONS 
In this study, the auditory acuity of hyperglycemic and normal subjects were 
studied. The variables influencing the auditory acuity were statistically analyzed 
which revealed the following:  
1. Incidence of hearing loss is common in diabetics when compared with 
normal subjects. 
2. Diabetes mellitus type 2 raises auditory threshold in all frequencies 
between 250 Hz and 8000 Hz in all age groups in this study when 
compared with controls 
3. The age and duration of diabetes affect auditory thresholds significantly 
in this study. 
4. There was no association between the glycemic status (except postprandial 
blood sugar), sex, and other micro vascular complications..This also shows 
that hyperglycemia along with duration of the disease is responsible for the 
microvascular complications 
5. Patients with peripheral neuropathy have statistically significant hearing loss 
of any frequency. 
  To conclude, auditory function of diabetic patients should be 
screened  early and regularly as hearing loss is one of the under 
recognized microvascular complications. 
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    The eighth nerve function in diabetes mellitus of adult 
PROFORMA 
Name:                                               Age /sex:                                       
Address: 
Occupation:                                      Income: 
Socio economic status: 
Whether diabetic / not 
Diagnosis: Type1/ Type2/ MODY 
Duration of illness: 
When it was first diagnosed: 
Symptoms at the time of presentation: 
Any associated complications at the time of diagnosis: 
               Microvascular 
               Macrovascular 
Other comorbid illness HT   /IHD /  CKD 
Start of therapy: OHA/ insulin 
Dosage of drugs: 
Any change in the therapy: 
If yes, why? 
 
 
Diabetic severity:  insulin dep/ insulin not dep/ no DM 
Whether compliance good/ poor 
On regular blood sugar check up:  
Whether HBA1c done at any point of time: 
Is there any hard of hearing at the time of diagnosis:  yes/no 
Is there any hard of hearing at present: Y/N 
Any previous history of: Ear discharge /tinnitus/ ear pain 
Any previous history of surgeries in the ear: Y/N 
Any family history of deafness: Y/N 
Any chronic history of drug intake Y/N 
History of usage of hearing aid or not 
History of exposure to loud noises Y/ N 
H/o of trauma to ear Y/N 
Examination  
Wt                                  Ht 
General    Pallor          edema legs         dermapathy        fungal infections          
 Periarthritis shoulder         balanoprosthitis        ulcers             caries          
 Dentures                 periodonitis 
 
 
 
PR                       BP                          
CVS 
RS 
PA 
CNS  truncal neuropathy/ amyotrophy/ sensory neuropathy 
PNS- vibration sense 
         Monofilament- 
Investigations 
Recent blood sugar – post prandial                                                urine – 
albumin 
Fasting                                     sugar 
Bloodurea           deposits 
Serum creatinine 
Serum cholesterol    Retinopathy  
HBA1c 
Audiogram result 
 
  
 
 
 
MASTER CHART ‐ CONTROLS 
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2
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0
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4
0
0
0
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4
0
0
0
‐
8
0
0
0
 
M
E
A
N
 
A
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D
I
O
G
R
A
M
 
R
E
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U
L
T
 
102  134  1  1  1  ‐  ‐  ‐  ‐  5  R10L10  R0L0  R8L8  10 0 8 NORMAL 
80  136  1  1  1  ‐  ‐  ‐  ‐  6  R8L8  R10L10  R10L10  8 10 10 NORMAL 
98  112  1  1  1  ‐  ‐  ‐  ‐  5.5  R8L8  R8L8  R8L8  8 8 8 NORMAL 
78  122  1  1  1  ‐  ‐  ‐  ‐  4  R8L8  R0L0L0  R10L10  8 0 10 NORMAL 
67  98  1  1  1  ‐  ‐  ‐  ‐  6.1  R20L20  R25L20  R20L20  20 22.5 20 NORMAL 
111  145  1  1  1  ‐  +  ‐  ‐  5  R0L0  R10L10  R10L10  0 10 10 NORMAL 
78  122  1  1  1  ‐  ‐  +  +  4.5  R25L35  R35L35  R35L35  30 35 35 MILD 
85  132  1  1  1  ‐  ‐  ‐  ‐  5  R8L8  R8L8  R10L10  8 8 10 NORMAL 
110  143  1  1  1  ‐  ‐  +  +  4.8  R40L35  R38L40  R40L40  37.5 39 40 MILD 
68  110  1  1  1  ‐  ‐  ‐  ‐  5.4  R0L0  R0L0  R0L0  0 0 0 NORMAL 
97  126  1  1  1  ‐  ‐  ‐  ‐  6  R8L8  R10L10  R10L10  8 10 10 NORMAL 
79  128  1  1  1  ‐  ‐  ‐  ‐  4.6  R8L8  R8L8  R8L8  8 8 8 NORMAL 
89  132  1  1  1  +  1  ‐  ‐  5  R8L8  R0L0L0  R10L10  8 0 10 NORMAL 
74  120  1  1  1  ‐  ‐  ‐  ‐  5.2  R15L18  R18L20  R20L20  16.5 19 20 NORMAL 
89  132  1  1  1  ‐  ‐  ‐  ‐  4  R18L18  R20L20  R20L20  18 20 20 NORMAL 
67  100  1  1  1  ‐  ‐  ‐  ‐  4.6  R10L10  R10L10  R10L10  10 10 10 NORMAL 
61  104  1  1  1  ‐  ‐  ‐  ‐  4.4  R10L10  R15L18  R15L20  10 16.5 17.5 NORMAL 
69  108  1  1  1  ‐  ‐  +  +  4  R28L30  R35L35  R40L40  29 35 40 MILD 
74  124  1  1  1  ‐  ‐  ‐  ‐  4  R18L18  R20L20  R20L20  18 20 20 NORMAL 
86  110  1  1  1  ‐  ‐  ‐  ‐  5  R8L8  R8L8  R10L10  8 8 10 NORMAL 
       MASTER CHART ‐ CONTROLS 
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47  1  102  134  1  1  1  ‐   ‐   ‐   ‐  5 R10L10  R0L0  R8L8  10 0 8 NORMAL   
49  1  80  136  1  1  1  ‐   ‐   ‐   ‐  6 R8L8  R10L10  R10L10  8 10 10 NORMAL   
55  1  98  112  1  1  1  ‐   ‐   ‐   ‐  5.5 R8L8  R8L8  R8L8  8 8 8 NORMAL   
60  2  78  122  1  1  1  ‐   ‐   ‐   ‐  4 R8L8  R0L0L0  R10L10  8 0 10 NORMAL   
57  1  67  98  1  1  1  ‐   ‐   ‐   ‐  6.1 R20L20  R25L20  R20L20  20 22.5 20 NORMAL   
49  2  111  145  1  1  1  ‐   +   ‐   ‐  5 R0L0  R10L10  R10L10  0 10 10 NORMAL   
58  1  78  122  1  1  1  ‐   ‐   +   +  4.5 R25L35  R35L35  R35L35  30 35 35 MILD   
52  1  85  132  1  1  1   ‐   ‐   ‐   ‐  5 R8L8  R8L8  R10L10  8 8 10 NORMAL   
56  2  110  143  1  1  1  ‐   ‐   +   +  4.8 R40L35  R38L40  R40L40  37.5 39 40 MILD   
47  2  68  110  1  1  1  ‐   ‐   ‐   ‐  5.4 R0L0  R0L0  R0L0  0 0 0 NORMAL   
49  2  97  126  1  1  1  ‐   ‐   ‐   ‐  6 R8L8  R10L10  R10L10  8 10 10 NORMAL   
52  2  79  128  1  1  1  ‐   ‐   ‐   ‐  4.6 R8L8  R8L8  R8L8  8 8 8 NORMAL   
52  1  89  132  1  1  1  +  1  ‐   ‐  5 R8L8  R0L0L0  R10L10  8 0 10 NORMAL   
47  1  74  120  1  1  1  ‐   ‐   ‐   ‐  5.2 R15L18  R18L20  R20L20  16.5 19 20 NORMAL   
48  1  89  132  1  1  1  ‐   ‐   ‐   ‐  4 R18L18  R20L20  R20L20  18 20 20 NORMAL   
51  1  67  100  1  1  1  ‐   ‐   ‐   ‐  4.6 R10L10  R10L10  R10L10  10 10 10 NORMAL   
57  2  61  104  1  1  1  ‐   ‐   ‐   ‐  4.4 R10L10  R15L18  R15L20  10 16.5 17.5 NORMAL   
59  2  69  108  1  1  1  ‐   ‐   +   +  4 R28L30  R35L35  R40L40  29 35 40 MILD   
42  1  74  124  1  1  1  ‐   ‐   ‐   ‐  4 R18L18  R20L20  R20L20  18 20 20 NORMAL   
50  1  86  110  1  1  1 ‐  ‐  ‐  ‐  5 R8L8  R8L8  R10L10  8 8 10 NORMAL   
 
 
 





